AN2 Therapeutics — Third Quarter 2026 Earnings Summary

AN2 Therapeutics reported a net loss of $8.0 million for the third quarter of 2026, with cash and investments totaling $80.2 million as of September 30, 2026. The company received regulatory clearance to proceed with its global Phase 2 study of oral epetraborole for polycythemia vera and expects to initiate enrollment by the end of 2026. Additionally, enrollment is ongoing for an investigator-initiated Phase 2 trial of epetraborole in M. abscessus lung disease, while startup activities have begun for a Phase 2 study of AN2-502998 in chronic Chagas disease. The company also selected AN2-504661 as a development candidate for hypophosphatasia and appointed Cameron Trenor, M.D., as its new Chief Medical Officer.